FIELD: medicine.
SUBSTANCE: VEGF-A concentration is determined in serum and if VEGF-A level is above 317 pg/ml, acute cellular rejection is diagnosed.
EFFECT: diagnostic simplicity, accessibility, non-invasiveness, reduced time of its implementation while achieving reliable diagnostic screening of acute cellular rejection both in the early and in the late post-transplant period in heart recipients, improved results of heart transplantation, increased recipient survival rates due to timely determination of indications for unscheduled endomyocardial biopsy, coronary and clarified treatment tactics by determining the level of VEGF-A concentration in the serum.
2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF SCREENING DIAGNOSTICS OF ACUTE CELLULAR REJECTION OF TRANSPLANTED HEART | 2016 |
|
RU2614726C1 |
| METHOD FOR DIAGNOSING ACUTE GRAFT REJECTION IN HEART RECIPIENTS | 2021 |
|
RU2759049C1 |
| METHOD FOR NON-INVASIVE DIAGNOSIS OF MYOCARDIAL FIBROSIS OF TRANSPLANTED HEART AT A LONG POST-TRANSPLANTATION PERIOD IN RECIPIENTS SUFFERING ACUTE REJECTION | 2019 |
|
RU2709193C1 |
| METHOD FOR DIAGNOSING ACUTE REJECTION OF TRANSPLANT IN TRANSPLANTED HEART RECIPIENT | 2020 |
|
RU2758973C1 |
| METHOD FOR NONINVASIVE DIAGNOSIS OF MYOCARDIAL FIBROSIS OF CARDIAC ALLOGRAFT | 2021 |
|
RU2772054C1 |
| METHOD FOR DIAGNOSING ACUTE TRANSPLANT REJECTION IN TRANSPLANTED HEART RECIPIENTS | 2020 |
|
RU2758994C1 |
| METHOD FOR PREOPERATIVE PREDICTION OF ACUTE CELLULAR REJECTION OF A TRANSPLANTED HEART | 2022 |
|
RU2798948C1 |
| METHOD FOR ESTIMATING EFFICIENCY OF IMMUNOSUPPRESSIVE THERAPY IN RECIPIENTS OF TRANSPLANTED HEART | 2015 |
|
RU2609794C1 |
| METHOD FOR NON-INVASIVE DIAGNOSIS OF MYOCARDIAL FIBROSIS IN CARDIAC TRANSPLANT RECIPIENTS | 2021 |
|
RU2760093C1 |
| METHOD FOR NON-INVASIVE DIAGNOSIS OF MYOCARDIAL FIBROSIS IN TRANSPLANTED HEART | 2021 |
|
RU2758993C1 |
